Peripheral Arterial Disease
Conditions
Brief summary
A prospective randomized trial to validate the efficacy and safety of rapamycin coated peripheral balloon catheter in the treatment of femoral popliteal artery disease.
Interventions
PROCEDUREPercutaneous selective arteriography of peripheral arteries
Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.
Sponsors
Shanghai Bomaian Medical Technology Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with arteriosclerosis obliterans of lower extremities, and Rutherford's rating is 2-5. * Patients with severe stenosis (≥ 70%) or occlusion of superficial femoral artery and/or proximal popliteal artery (within P1 stage) * Patients with total length of target lesion ≤ 20cm and length of occluded segment ≤ 15cm (the distance between two segments of lesions less than 2cm is considered as the same lesion) * Those who agree to participate in this clinical trial and sign the informed consent form
Exclusion criteria
： * This operation is planned to intervene patients with bilateral lower limbs. * Patients whose guide wire fails to pass through the target lesion. * Patients whose target lesion is in stent restenosis (ISR). * ≥ 2 lesions need to be treated in the target vessel (if the distance between two lesions is less than 2cm, it is considered as the same lesion). * Patients with target lesions requiring rotary resection/laser therapy/thrombus aspiration for this treatment. * Patients with ipsilateral iliac artery inflow tract lesions that cannot be successfully treated (i.e. residual stenosis ≥ 30% after treatment). * There is less than one unobstructed blood vessel under the knee of the target limb before operation (unobstructed is defined as visual stenosis\<50%). * Residual stenosis ≥ 30% after pre expansion of target lesion or severe (≥ Grade D) flow limiting dissection. * Patients with obviously abnormal renal function (creatinine \> 2.5mg/dL or 220umol/L) or undergoing dialysis. * Patients with severe liver dysfunction who are judged by the researcher to be unsuitable for surgery. * Patients with severe coagulation dysfunction or uncontrolled severe infection who are not suitable for surgery. * Patients who have performed distal amputation (above metatarsal) on the affected or opposite limb in the past. * Patients who received local or systemic thrombolytic therapy within 48 hours before surgery. * Patients receiving vascular interventional therapy or surgical treatment on target limb within 30 days before operation. * Patients known to be allergic to aspirin, clopidogrel, paclitaxel and rapamycin. * Pregnant or lactating women and patients with family planning during the study * Patients who are participating in clinical trials of other drugs or medical devices but are not included in the group. * Patients with life expectancy less than 12 months * Patients not suitable for this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| primary patency rate, PPR. | 12months | It is defined as:Primary patency of target lesion: the target lesion is patency (systolic peak blood flow ratio\<2.4) and there is no clinically driven target lesion revascularization (TLR) by Doppler ultrasound. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Device success rate | The day of operation. | It is defined as: the balloon catheter can reach the target lesion, expand successfully, without rupture, and withdraw successfully. |
| Operation success rate | 1DAY | The success of surgery was defined as: residual stenosis ≤ 50% (without salvage stent implantation) or ≤ 30% (with salvage stent implantation). |
| Target Lesion Revascularization incidence. | 12 months after operation. | Target Lesion Revascularization is defined as any re intervention treatment required in the target lesion. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Incidence rate of major adverse events | 12 months after operation. | Major adverse events were defined as: all cause death at 30 days, amputation of diseased limbs 12 months after operation, and clinically driven target vessel revascularization |
| Occurrence of other adverse events and serious adverse events | 12 months after operation. | Evaluation method: other adverse events and serious adverse events of the subjects were recorded through telephone/hospital visit. |
Countries
China
Contacts
Primary ContactWei Guo
Outcome results
None listed